10 November,2020 01:03 PM IST | New York | IANS
This picture has been used for representational purposes
Drug regulators in the US have given emergency use approval for Eli Lilly and Co's investigational monoclonal antibody therapy for the treatment of mild-to-moderate Covid-19 in adult and pediatric patients.
The treatment called, bamlanivimab, is authorised for patients with positive results of direct SARS-CoV-2 viral testing who are 12 years of age and older weighing at least 40kg, and who are at high risk for progressing to severe Covid-19 and/or hospitalisation, the US Food and Drug Administration (FDA) said on Monday.
ALSO READ
Video shows NY officer fatally shooting 13-year-old
Imran Khan's party blames Pak's Interior Minister of ordered ear gas to be fired
Joe Biden talks election, economy and Middle East in surprise news briefing
Dunedin, New Zealand, records wettest day in century
Israel cuts off key crossing into Syria
In clinical trials, the treatment was shown in to reduce Covid-19-related hospitalisation or emergency room visits.
Monoclonal antibodies are laboratory-made proteins that mimic the immune system's ability to fight off harmful antigens such as viruses.
Bamlanivimab is a monoclonal antibody that is specifically directed against the spike protein of SARS-CoV-2, designed to block the virus' attachment and entry into human cells.
"The FDA's emergency authorisation of bamlanivimab provides health care professionals on the frontline of this pandemic with another potential tool in treating Covid-19 patients," said Patrizia Cavazzoni, Acting Director of the FDA's Center for Drug Evaluation and Research.
"We will continue to evaluate new data on the safety and efficacy of bamlanivimab as they become available."
However, the US FDA noted that bamlanivimab is not authorised for patients who are hospitalised due to Covid-19 or require oxygen therapy due to Covid-19.
A benefit of bamlanivimab treatment has not been shown in patients hospitalised due to Covid-19.
Catch up on all the latest Crime, National, International and Hatke news here. Also download the new mid-day Android and iOS apps to get latest updates.
Mid-Day is now on Telegram. Click here to join our channel (@middayinfomedialtd) and stay updated with the latest news
This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever
